Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9% saline on delayed graft function in deceased donor kidney transplantation
Delayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor kidney transplantation and is associated with inferior outcomes and higher costs. Intravenous fluids given during and after transplantation may affect the ri...
Saved in:
| Published in | Current controlled trials in cardiovascular medicine Vol. 21; no. 1; pp. 428 - 19 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
25.05.2020
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Delayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor kidney transplantation and is associated with inferior outcomes and higher costs. Intravenous fluids given during and after transplantation may affect the risk of poor kidney function after transplant. The most commonly used fluid, isotonic sodium chloride (0.9% saline), contains a high chloride concentration, which may be associated with acute kidney injury, and could increase the risk of delayed graft function. Whether using a balanced, low-chloride fluid instead of 0.9% saline is safe and improves kidney function after deceased donor kidney transplantation is unknown.
BEST-Fluids is an investigator-initiated, pragmatic, registry-based, multi-center, double-blind, randomized controlled trial. The primary objective is to compare the effect of intravenous Plasma-Lyte 148 (Plasmalyte), a balanced, low-chloride solution, with the effect of 0.9% saline on the incidence of delayed graft function in deceased donor kidney transplant recipients. From January 2018 onwards, 800 participants admitted for deceased donor kidney transplantation will be recruited over 3 years in Australia and New Zealand. Participants are randomized 1:1 to either intravenous Plasmalyte or 0.9% saline peri-operatively and until 48 h post-transplant, or until fluid is no longer required; whichever comes first. Follow up is for 1 year. The primary outcome is the incidence of delayed graft function, defined as dialysis in the first 7 days post-transplant. Secondary outcomes include early kidney transplant function (composite of dialysis duration and rate of improvement in graft function when dialysis is not required), hyperkalemia, mortality, graft survival, graft function, quality of life, healthcare resource use, and cost-effectiveness. Participants are enrolled, randomized, and followed up using the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry.
If using Plasmalyte instead of 0.9% saline is effective at reducing delayed graft function and improves other clinical outcomes in deceased donor kidney transplantation, this simple, inexpensive change to using a balanced low-chloride intravenous fluid at the time of transplantation could be easily implemented in the vast majority of transplant settings worldwide.
Australian New Zealand Clinical Trials Registry: ACTRN12617000358347. Registered on 8 March 2017. ClinicalTrials.gov: NCT03829488. Registered on 4 February 2019. |
|---|---|
| AbstractList | Delayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor kidney transplantation and is associated with inferior outcomes and higher costs. Intravenous fluids given during and after transplantation may affect the risk of poor kidney function after transplant. The most commonly used fluid, isotonic sodium chloride (0.9% saline), contains a high chloride concentration, which may be associated with acute kidney injury, and could increase the risk of delayed graft function. Whether using a balanced, low-chloride fluid instead of 0.9% saline is safe and improves kidney function after deceased donor kidney transplantation is unknown.
BEST-Fluids is an investigator-initiated, pragmatic, registry-based, multi-center, double-blind, randomized controlled trial. The primary objective is to compare the effect of intravenous Plasma-Lyte 148 (Plasmalyte), a balanced, low-chloride solution, with the effect of 0.9% saline on the incidence of delayed graft function in deceased donor kidney transplant recipients. From January 2018 onwards, 800 participants admitted for deceased donor kidney transplantation will be recruited over 3 years in Australia and New Zealand. Participants are randomized 1:1 to either intravenous Plasmalyte or 0.9% saline peri-operatively and until 48 h post-transplant, or until fluid is no longer required; whichever comes first. Follow up is for 1 year. The primary outcome is the incidence of delayed graft function, defined as dialysis in the first 7 days post-transplant. Secondary outcomes include early kidney transplant function (composite of dialysis duration and rate of improvement in graft function when dialysis is not required), hyperkalemia, mortality, graft survival, graft function, quality of life, healthcare resource use, and cost-effectiveness. Participants are enrolled, randomized, and followed up using the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry.
If using Plasmalyte instead of 0.9% saline is effective at reducing delayed graft function and improves other clinical outcomes in deceased donor kidney transplantation, this simple, inexpensive change to using a balanced low-chloride intravenous fluid at the time of transplantation could be easily implemented in the vast majority of transplant settings worldwide.
Australian New Zealand Clinical Trials Registry: ACTRN12617000358347. Registered on 8 March 2017. ClinicalTrials.gov: NCT03829488. Registered on 4 February 2019. BackgroundDelayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor kidney transplantation and is associated with inferior outcomes and higher costs. Intravenous fluids given during and after transplantation may affect the risk of poor kidney function after transplant. The most commonly used fluid, isotonic sodium chloride (0.9% saline), contains a high chloride concentration, which may be associated with acute kidney injury, and could increase the risk of delayed graft function. Whether using a balanced, low-chloride fluid instead of 0.9% saline is safe and improves kidney function after deceased donor kidney transplantation is unknown.MethodsBEST-Fluids is an investigator-initiated, pragmatic, registry-based, multi-center, double-blind, randomized controlled trial. The primary objective is to compare the effect of intravenous Plasma-Lyte 148 (Plasmalyte), a balanced, low-chloride solution, with the effect of 0.9% saline on the incidence of delayed graft function in deceased donor kidney transplant recipients. From January 2018 onwards, 800 participants admitted for deceased donor kidney transplantation will be recruited over 3 years in Australia and New Zealand. Participants are randomized 1:1 to either intravenous Plasmalyte or 0.9% saline peri-operatively and until 48 h post-transplant, or until fluid is no longer required; whichever comes first. Follow up is for 1 year. The primary outcome is the incidence of delayed graft function, defined as dialysis in the first 7 days post-transplant. Secondary outcomes include early kidney transplant function (composite of dialysis duration and rate of improvement in graft function when dialysis is not required), hyperkalemia, mortality, graft survival, graft function, quality of life, healthcare resource use, and cost-effectiveness. Participants are enrolled, randomized, and followed up using the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry.DiscussionIf using Plasmalyte instead of 0.9% saline is effective at reducing delayed graft function and improves other clinical outcomes in deceased donor kidney transplantation, this simple, inexpensive change to using a balanced low-chloride intravenous fluid at the time of transplantation could be easily implemented in the vast majority of transplant settings worldwide.Trial registrationAustralian New Zealand Clinical Trials Registry: ACTRN12617000358347. Registered on 8 March 2017. ClinicalTrials.gov: NCT03829488. Registered on 4 February 2019. Delayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor kidney transplantation and is associated with inferior outcomes and higher costs. Intravenous fluids given during and after transplantation may affect the risk of poor kidney function after transplant. The most commonly used fluid, isotonic sodium chloride (0.9% saline), contains a high chloride concentration, which may be associated with acute kidney injury, and could increase the risk of delayed graft function. Whether using a balanced, low-chloride fluid instead of 0.9% saline is safe and improves kidney function after deceased donor kidney transplantation is unknown.BACKGROUNDDelayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor kidney transplantation and is associated with inferior outcomes and higher costs. Intravenous fluids given during and after transplantation may affect the risk of poor kidney function after transplant. The most commonly used fluid, isotonic sodium chloride (0.9% saline), contains a high chloride concentration, which may be associated with acute kidney injury, and could increase the risk of delayed graft function. Whether using a balanced, low-chloride fluid instead of 0.9% saline is safe and improves kidney function after deceased donor kidney transplantation is unknown.BEST-Fluids is an investigator-initiated, pragmatic, registry-based, multi-center, double-blind, randomized controlled trial. The primary objective is to compare the effect of intravenous Plasma-Lyte 148 (Plasmalyte), a balanced, low-chloride solution, with the effect of 0.9% saline on the incidence of delayed graft function in deceased donor kidney transplant recipients. From January 2018 onwards, 800 participants admitted for deceased donor kidney transplantation will be recruited over 3 years in Australia and New Zealand. Participants are randomized 1:1 to either intravenous Plasmalyte or 0.9% saline peri-operatively and until 48 h post-transplant, or until fluid is no longer required; whichever comes first. Follow up is for 1 year. The primary outcome is the incidence of delayed graft function, defined as dialysis in the first 7 days post-transplant. Secondary outcomes include early kidney transplant function (composite of dialysis duration and rate of improvement in graft function when dialysis is not required), hyperkalemia, mortality, graft survival, graft function, quality of life, healthcare resource use, and cost-effectiveness. Participants are enrolled, randomized, and followed up using the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry.METHODSBEST-Fluids is an investigator-initiated, pragmatic, registry-based, multi-center, double-blind, randomized controlled trial. The primary objective is to compare the effect of intravenous Plasma-Lyte 148 (Plasmalyte), a balanced, low-chloride solution, with the effect of 0.9% saline on the incidence of delayed graft function in deceased donor kidney transplant recipients. From January 2018 onwards, 800 participants admitted for deceased donor kidney transplantation will be recruited over 3 years in Australia and New Zealand. Participants are randomized 1:1 to either intravenous Plasmalyte or 0.9% saline peri-operatively and until 48 h post-transplant, or until fluid is no longer required; whichever comes first. Follow up is for 1 year. The primary outcome is the incidence of delayed graft function, defined as dialysis in the first 7 days post-transplant. Secondary outcomes include early kidney transplant function (composite of dialysis duration and rate of improvement in graft function when dialysis is not required), hyperkalemia, mortality, graft survival, graft function, quality of life, healthcare resource use, and cost-effectiveness. Participants are enrolled, randomized, and followed up using the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry.If using Plasmalyte instead of 0.9% saline is effective at reducing delayed graft function and improves other clinical outcomes in deceased donor kidney transplantation, this simple, inexpensive change to using a balanced low-chloride intravenous fluid at the time of transplantation could be easily implemented in the vast majority of transplant settings worldwide.DISCUSSIONIf using Plasmalyte instead of 0.9% saline is effective at reducing delayed graft function and improves other clinical outcomes in deceased donor kidney transplantation, this simple, inexpensive change to using a balanced low-chloride intravenous fluid at the time of transplantation could be easily implemented in the vast majority of transplant settings worldwide.Australian New Zealand Clinical Trials Registry: ACTRN12617000358347. Registered on 8 March 2017. ClinicalTrials.gov: NCT03829488. Registered on 4 February 2019.TRIAL REGISTRATIONAustralian New Zealand Clinical Trials Registry: ACTRN12617000358347. Registered on 8 March 2017. ClinicalTrials.gov: NCT03829488. Registered on 4 February 2019. Abstract Background Delayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor kidney transplantation and is associated with inferior outcomes and higher costs. Intravenous fluids given during and after transplantation may affect the risk of poor kidney function after transplant. The most commonly used fluid, isotonic sodium chloride (0.9% saline), contains a high chloride concentration, which may be associated with acute kidney injury, and could increase the risk of delayed graft function. Whether using a balanced, low-chloride fluid instead of 0.9% saline is safe and improves kidney function after deceased donor kidney transplantation is unknown. Methods BEST-Fluids is an investigator-initiated, pragmatic, registry-based, multi-center, double-blind, randomized controlled trial. The primary objective is to compare the effect of intravenous Plasma-Lyte 148 (Plasmalyte), a balanced, low-chloride solution, with the effect of 0.9% saline on the incidence of delayed graft function in deceased donor kidney transplant recipients. From January 2018 onwards, 800 participants admitted for deceased donor kidney transplantation will be recruited over 3 years in Australia and New Zealand. Participants are randomized 1:1 to either intravenous Plasmalyte or 0.9% saline peri-operatively and until 48 h post-transplant, or until fluid is no longer required; whichever comes first. Follow up is for 1 year. The primary outcome is the incidence of delayed graft function, defined as dialysis in the first 7 days post-transplant. Secondary outcomes include early kidney transplant function (composite of dialysis duration and rate of improvement in graft function when dialysis is not required), hyperkalemia, mortality, graft survival, graft function, quality of life, healthcare resource use, and cost-effectiveness. Participants are enrolled, randomized, and followed up using the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry. Discussion If using Plasmalyte instead of 0.9% saline is effective at reducing delayed graft function and improves other clinical outcomes in deceased donor kidney transplantation, this simple, inexpensive change to using a balanced low-chloride intravenous fluid at the time of transplantation could be easily implemented in the vast majority of transplant settings worldwide. Trial registration Australian New Zealand Clinical Trials Registry: ACTRN12617000358347 . Registered on 8 March 2017. ClinicalTrials.gov: NCT03829488 . Registered on 4 February 2019. Delayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor kidney transplantation and is associated with inferior outcomes and higher costs. Intravenous fluids given during and after transplantation may affect the risk of poor kidney function after transplant. The most commonly used fluid, isotonic sodium chloride (0.9% saline), contains a high chloride concentration, which may be associated with acute kidney injury, and could increase the risk of delayed graft function. Whether using a balanced, low-chloride fluid instead of 0.9% saline is safe and improves kidney function after deceased donor kidney transplantation is unknown. BEST-Fluids is an investigator-initiated, pragmatic, registry-based, multi-center, double-blind, randomized controlled trial. The primary objective is to compare the effect of intravenous Plasma-Lyte 148 (Plasmalyte), a balanced, low-chloride solution, with the effect of 0.9% saline on the incidence of delayed graft function in deceased donor kidney transplant recipients. From January 2018 onwards, 800 participants admitted for deceased donor kidney transplantation will be recruited over 3 years in Australia and New Zealand. Participants are randomized 1:1 to either intravenous Plasmalyte or 0.9% saline peri-operatively and until 48 h post-transplant, or until fluid is no longer required; whichever comes first. Follow up is for 1 year. The primary outcome is the incidence of delayed graft function, defined as dialysis in the first 7 days post-transplant. Secondary outcomes include early kidney transplant function (composite of dialysis duration and rate of improvement in graft function when dialysis is not required), hyperkalemia, mortality, graft survival, graft function, quality of life, healthcare resource use, and cost-effectiveness. Participants are enrolled, randomized, and followed up using the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry. If using Plasmalyte instead of 0.9% saline is effective at reducing delayed graft function and improves other clinical outcomes in deceased donor kidney transplantation, this simple, inexpensive change to using a balanced low-chloride intravenous fluid at the time of transplantation could be easily implemented in the vast majority of transplant settings worldwide. Background Delayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor kidney transplantation and is associated with inferior outcomes and higher costs. Intravenous fluids given during and after transplantation may affect the risk of poor kidney function after transplant. The most commonly used fluid, isotonic sodium chloride (0.9% saline), contains a high chloride concentration, which may be associated with acute kidney injury, and could increase the risk of delayed graft function. Whether using a balanced, low-chloride fluid instead of 0.9% saline is safe and improves kidney function after deceased donor kidney transplantation is unknown. Methods BEST-Fluids is an investigator-initiated, pragmatic, registry-based, multi-center, double-blind, randomized controlled trial. The primary objective is to compare the effect of intravenous Plasma-Lyte 148 (Plasmalyte), a balanced, low-chloride solution, with the effect of 0.9% saline on the incidence of delayed graft function in deceased donor kidney transplant recipients. From January 2018 onwards, 800 participants admitted for deceased donor kidney transplantation will be recruited over 3 years in Australia and New Zealand. Participants are randomized 1:1 to either intravenous Plasmalyte or 0.9% saline peri-operatively and until 48 h post-transplant, or until fluid is no longer required; whichever comes first. Follow up is for 1 year. The primary outcome is the incidence of delayed graft function, defined as dialysis in the first 7 days post-transplant. Secondary outcomes include early kidney transplant function (composite of dialysis duration and rate of improvement in graft function when dialysis is not required), hyperkalemia, mortality, graft survival, graft function, quality of life, healthcare resource use, and cost-effectiveness. Participants are enrolled, randomized, and followed up using the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry. Discussion If using Plasmalyte instead of 0.9% saline is effective at reducing delayed graft function and improves other clinical outcomes in deceased donor kidney transplantation, this simple, inexpensive change to using a balanced low-chloride intravenous fluid at the time of transplantation could be easily implemented in the vast majority of transplant settings worldwide. Trial registration Australian New Zealand Clinical Trials Registry: ACTRN12617000358347. Registered on 8 March 2017. ClinicalTrials.gov: NCT03829488. Registered on 4 February 2019. Keywords: Balanced crystalloid, Delayed graft function, End-stage kidney disease, Intravenous fluids, Kidney transplantation, Peri-operative care, Plasma-Lyte 148, Pragmatic trial, Registry trial, Normal saline |
| ArticleNumber | 428 |
| Audience | Academic |
| Author | Reidlinger, Donna Clayton, Philip A. Howard, Kirsten Johnson, David W. Varghese, Julie Dansie, Kathryn B. Hawley, Carmel M. Collins, Michael G. McArthur, Colin J. Weinberg, Laurence Robison, Laura Vergara, Liza A. McConnochie, Rachael C. Fahim, Magid A. Pascoe, Elaine M. Chadban, Steven J. Mount, Peter F. |
| Author_xml | – sequence: 1 givenname: Michael G. orcidid: 0000-0003-2169-9087 surname: Collins fullname: Collins, Michael G. – sequence: 2 givenname: Magid A. surname: Fahim fullname: Fahim, Magid A. – sequence: 3 givenname: Elaine M. surname: Pascoe fullname: Pascoe, Elaine M. – sequence: 4 givenname: Kathryn B. surname: Dansie fullname: Dansie, Kathryn B. – sequence: 5 givenname: Carmel M. surname: Hawley fullname: Hawley, Carmel M. – sequence: 6 givenname: Philip A. surname: Clayton fullname: Clayton, Philip A. – sequence: 7 givenname: Kirsten surname: Howard fullname: Howard, Kirsten – sequence: 8 givenname: David W. surname: Johnson fullname: Johnson, David W. – sequence: 9 givenname: Colin J. surname: McArthur fullname: McArthur, Colin J. – sequence: 10 givenname: Rachael C. surname: McConnochie fullname: McConnochie, Rachael C. – sequence: 11 givenname: Peter F. surname: Mount fullname: Mount, Peter F. – sequence: 12 givenname: Donna surname: Reidlinger fullname: Reidlinger, Donna – sequence: 13 givenname: Laura surname: Robison fullname: Robison, Laura – sequence: 14 givenname: Julie surname: Varghese fullname: Varghese, Julie – sequence: 15 givenname: Liza A. surname: Vergara fullname: Vergara, Liza A. – sequence: 16 givenname: Laurence surname: Weinberg fullname: Weinberg, Laurence – sequence: 17 givenname: Steven J. surname: Chadban fullname: Chadban, Steven J. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32450917$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9U1tPFTEQXg1GLvoHfDBNjAkmLHYv3YsPJoCgJCSSgM9Nt50eij3tse0ec_z1znJAgRjTh-3OfPPNNzOd7WzDeQdZ9qqg-0XRNe9jUdGmymlJc1pXrM_Lp9lW0dYsb8qCbdy7b2bbMV5TRPVV_TzbrMqa0b5ot558ukijWpHz4JOX3hLtAzmElCCQ46VR4CTc2C7AgkzGzchlEC4urHCJnNjRqEh2D48vLvP1z7sPRJBFELO5SEbukQAzE1NY5YOIoPbIfLTJ5BIcZtgjyo-DhXywxqEPiZWfm1-giPQuBW8tXlMwwhJYCjuKGwHpCghojXKI18QgUCzB-TESPUmY_EEsVuSnSVfk3Io4F_nZKgEp6o4sIURE0v3-LYkC8wLxjiiwYoW5ZkHoRPTosFQ0m8kjYVKOUh224btRDlao6a4HYgK-yJ5pYSO8vP3uZN9Oji-PvuRnXz-fHh2c5ZI1Vcq1KJsBRdBO664om1or1cpOQQFSCkqBdkXHykZXIGsKhaBD27WNHFrFBk1ptZOdrnmVF9d8EcxchBX3wvAbgw8zLgK23QIXdd1Lxsq-lW2tpB4qTMkaaJlQ3cBa5Pq45lqMwxzUNJEg7APShx5nrvjML3lb1n1dTWJ2bwmC_zFCTHxuogSLXQEcBi9r2vSsLNseoW8eQa_9GBy2ipctUlV9U7R_UTOBBRinPeaVEyk_aBDHWM8mrv1_oPAomBt8NqAN2h8EvL5f6J8K73YAAd0aIIOPMYDm0qzniszG8oLyad34et04rhu_WTdeYmj5KPSO_T9BvwExDjJp |
| CitedBy_id | crossref_primary_10_1111_ajco_13670 crossref_primary_10_1186_s13063_021_05989_w crossref_primary_10_1097_ALN_0000000000003948 crossref_primary_10_1016_j_bjane_2021_08_015 crossref_primary_10_1016_S1769_7255_22_00572_7 crossref_primary_10_3349_ymj_2022_63_4_380 crossref_primary_10_1016_j_xkme_2022_100472 crossref_primary_10_1097_TP_0000000000003582 crossref_primary_10_1097_TXD_0000000000001399 crossref_primary_10_1097_SLA_0000000000005620 crossref_primary_10_21926_obm_transplant_2302181 crossref_primary_10_1016_S0140_6736_23_00642_6 crossref_primary_10_1186_s13063_024_08209_3 crossref_primary_10_1111_tri_14132 |
| Cites_doi | 10.1097/SLA.0b013e31825074f5 10.1001/jama.2012.13356 10.1136/bmj.317.7155.362 10.1097/SLA.0b013e318256be72 10.1002/bjs.9651 10.1056/NEJMoa1711586 10.1111/j.1600-6143.2004.00488.x 10.1093/ndt/gfn667 10.1681/ASN.2008030287 10.1093/bja/aex163 10.1038/ki.2015.190 10.1186/s13054-015-1045-z 10.1164/rccm.201607-1345OC 10.1093/ndt/gfz090 10.1213/ANE.0b013e318293d81e 10.1172/JCI110820 10.1097/TP.0b013e3181ac620b 10.1177/0310057X1804600112 10.1111/j.1600-6143.2010.03179.x 10.1016/S0041-1345(02)03593-5 10.1038/nrneph.2010.33 10.1016/j.jbi.2008.08.010 10.1038/ki.2014.105 10.1097/ALN.0000000000003130 10.1097/TP.0b013e3182855544 10.1001/jama.2009.1310 10.1097/TP.0000000000001409 10.1136/bmj.h2147 10.1007/s00134-017-4772-6 10.1111/j.1600-6143.2011.03686.x 10.1097/TP.0000000000000450 10.1093/ckj/sfx040 10.1056/NEJMoa1711584 10.1097/01.TP.0000121763.44137.FA 10.1038/ki.2014.18 10.1371/journal.pmed.1001307 10.1056/NEJMoa1801601 10.1056/NEJMoa1501969 10.7326/0003-4819-150-9-200905050-00006 10.1001/jama.2015.12334 10.1097/TP.0b013e3182a19348 10.1056/NEJMoa1405707 10.5492/wjccm.v5.i4.235 10.1097/CCM.0000000000000305 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2020 BioMed Central Ltd. The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2020 |
| Copyright_xml | – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2020 |
| CorporateAuthor | for the BEST-Fluids Investigators and the Australasian Kidney Trials Network BEST-Fluids Investigators and the Australasian Kidney Trials Network |
| CorporateAuthor_xml | – name: for the BEST-Fluids Investigators and the Australasian Kidney Trials Network – name: BEST-Fluids Investigators and the Australasian Kidney Trials Network |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13063-020-04359-2 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea ProQuest Health & Medical Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1745-6215 |
| EndPage | 19 |
| ExternalDocumentID | oai_doaj_org_article_a449c55297c74dcfb3f8156e75ad8b57 PMC7249430 A627355959 32450917 10_1186_s13063_020_04359_2 |
| Genre | Clinical Trial Protocol Journal Article |
| GeographicLocations | Australia New Zealand Sydney New South Wales Australia Melbourne Victoria Australia Adelaide South Australia Australia |
| GeographicLocations_xml | – name: Australia – name: New Zealand – name: Adelaide South Australia Australia – name: Melbourne Victoria Australia – name: Sydney New South Wales Australia |
| GrantInformation_xml | – fundername: Baxter Healthcare Corporation grantid: Baxter Medication Delivery Grant 2017 – fundername: Department of Health, Australian Government grantid: APP1152390 – fundername: Royal Australasian College of Physicians grantid: Jacquot Research Establishment Award 2017 – fundername: National Health and Medical Research Council grantid: APP1092957 – fundername: Health Research Council of New Zealand grantid: 17/414 – fundername: ; grantid: APP1152390 – fundername: ; grantid: Baxter Medication Delivery Grant 2017 – fundername: ; grantid: 17/414 – fundername: ; grantid: APP1092957 – fundername: ; grantid: Jacquot Research Establishment Award 2017 |
| GroupedDBID | --- 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACUHS ADBBV ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ O5R O5S OVT PGMZT PHGZM PHGZT PIMPY PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 5GY 7XB 8FK AHMBA AZQEC DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS XSB 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c563t-fa26b14808ff81264fdd7c8de1ecca00e0818526f3ec40e1a0b7876cb7d5bf003 |
| IEDL.DBID | M48 |
| ISSN | 1745-6215 |
| IngestDate | Wed Aug 27 01:20:47 EDT 2025 Thu Aug 21 18:09:32 EDT 2025 Sun Aug 24 04:01:15 EDT 2025 Fri Jul 25 21:59:38 EDT 2025 Tue Jun 17 21:25:57 EDT 2025 Tue Jun 10 20:41:35 EDT 2025 Mon Jul 21 05:59:23 EDT 2025 Thu Apr 24 23:07:39 EDT 2025 Tue Jul 01 04:00:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | End-stage kidney disease Normal saline Balanced crystalloid Plasma-Lyte 148 Peri-operative care Pragmatic trial Registry trial Delayed graft function Intravenous fluids Kidney transplantation |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c563t-fa26b14808ff81264fdd7c8de1ecca00e0818526f3ec40e1a0b7876cb7d5bf003 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Undefined-1 content type line 23 |
| ORCID | 0000-0003-2169-9087 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13063-020-04359-2 |
| PMID | 32450917 |
| PQID | 2730339617 |
| PQPubID | 44365 |
| PageCount | 19 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a449c55297c74dcfb3f8156e75ad8b57 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7249430 proquest_miscellaneous_2406952279 proquest_journals_2730339617 gale_infotracmisc_A627355959 gale_infotracacademiconefile_A627355959 pubmed_primary_32450917 crossref_citationtrail_10_1186_s13063_020_04359_2 crossref_primary_10_1186_s13063_020_04359_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-05-25 |
| PublicationDateYYYYMMDD | 2020-05-25 |
| PublicationDate_xml | – month: 05 year: 2020 text: 2020-05-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAlternate | Trials |
| PublicationYear | 2020 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | SG Yarlagadda (4359_CR6) 2009; 24 K Maheshwari (4359_CR36) 2020; 132 E Rodrigo (4359_CR38) 2004; 4 AD Shaw (4359_CR22) 2012; 255 L Weinberg (4359_CR29) 2017; 119 CS Wilcox (4359_CR17) 1983; 71 DN Lobo (4359_CR16) 2014; 86 NM Yunos (4359_CR23) 2012; 308 P Schnuelle (4359_CR12) 2009; 302 PA Clayton (4359_CR42) 2019; 34 B Schroppel (4359_CR10) 2014; 86 GJ Schwartz (4359_CR28) 2009; 20 WD Irish (4359_CR9) 2010; 10 CM O'Malley (4359_CR14) 2002; 34 M Tonelli (4359_CR1) 2011; 11 SJ Tingle (4359_CR13) 2019; 3 WK Wu (4359_CR7) 2015; 88 EG Hagenmeyer (4359_CR5) 2004; 77 AD Shaw (4359_CR32) 2015; 19 PS Myles (4359_CR47) 2018; 378 JA Kraut (4359_CR18) 2010; 6 M Wyld (4359_CR2) 2012; 9 L Weinberg (4359_CR25) 2016; 5 cr-split#-4359_CR46.2 cr-split#-4359_CR46.1 K Raghunathan (4359_CR31) 2014; 42 P Young (4359_CR35) 2015; 314 MW Semler (4359_CR21) 2018; 378 D McIlroy (4359_CR37) 2017; 43 T Treasure (4359_CR40) 1998; 317 CU Niemann (4359_CR11) 2015; 373 WH Self (4359_CR20) 2018; 378 K Loudon (4359_CR26) 2015; 350 SA McCluskey (4359_CR30) 2013; 117 PA Harris (4359_CR44) 2009; 42 PS Rao (4359_CR43) 2009; 88 BJ Orandi (4359_CR41) 2015; 99 AH Chowdhury (4359_CR15) 2012; 256 S Wan (4359_CR24) 2016; 8 DH Mallon (4359_CR4) 2013; 96 MW Semler (4359_CR34) 2017; 195 A Adwaney (4359_CR39) 2017; 10 IE Hall (4359_CR3) 2017; 101 L Weinberg (4359_CR33) 2018; 46 B Lagerqvist (4359_CR45) 2014; 371 AS Levey (4359_CR27) 2009; 150 NM Butala (4359_CR8) 2013; 95 ML Krajewski (4359_CR19) 2015; 102 |
| References_xml | – volume: 255 start-page: 821 issue: 5 year: 2012 ident: 4359_CR22 publication-title: Ann Surg doi: 10.1097/SLA.0b013e31825074f5 – ident: #cr-split#-4359_CR46.1 – volume: 308 start-page: 1566 issue: 15 year: 2012 ident: 4359_CR23 publication-title: JAMA doi: 10.1001/jama.2012.13356 – volume: 317 start-page: 362 issue: 7155 year: 1998 ident: 4359_CR40 publication-title: BMJ doi: 10.1136/bmj.317.7155.362 – volume: 256 start-page: 18 issue: 1 year: 2012 ident: 4359_CR15 publication-title: Ann Surg doi: 10.1097/SLA.0b013e318256be72 – volume: 102 start-page: 24 issue: 1 year: 2015 ident: 4359_CR19 publication-title: Br J Surg doi: 10.1002/bjs.9651 – volume: 378 start-page: 819 issue: 9 year: 2018 ident: 4359_CR20 publication-title: N Engl J Med doi: 10.1056/NEJMoa1711586 – volume: 4 start-page: 1163 issue: 7 year: 2004 ident: 4359_CR38 publication-title: Am J Transplant doi: 10.1111/j.1600-6143.2004.00488.x – volume: 24 start-page: 1039 issue: 3 year: 2009 ident: 4359_CR6 publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfn667 – volume: 20 start-page: 629 issue: 3 year: 2009 ident: 4359_CR28 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2008030287 – volume: 119 start-page: 606 issue: 4 year: 2017 ident: 4359_CR29 publication-title: Br J Anaesth doi: 10.1093/bja/aex163 – volume: 88 start-page: 851 issue: 4 year: 2015 ident: 4359_CR7 publication-title: Kidney Int doi: 10.1038/ki.2015.190 – volume: 19 start-page: 334 year: 2015 ident: 4359_CR32 publication-title: Crit Care doi: 10.1186/s13054-015-1045-z – volume: 195 start-page: 1362 issue: 10 year: 2017 ident: 4359_CR34 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201607-1345OC – volume: 34 start-page: 2127 issue: 12 year: 2019 ident: 4359_CR42 publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfz090 – volume: 117 start-page: 412 issue: 2 year: 2013 ident: 4359_CR30 publication-title: Anesth Analg doi: 10.1213/ANE.0b013e318293d81e – volume: 71 start-page: 726 issue: 3 year: 1983 ident: 4359_CR17 publication-title: J Clin Invest doi: 10.1172/JCI110820 – volume: 88 start-page: 231 issue: 2 year: 2009 ident: 4359_CR43 publication-title: Transplantation doi: 10.1097/TP.0b013e3181ac620b – volume: 46 start-page: 79 issue: 1 year: 2018 ident: 4359_CR33 publication-title: Anaesth Intensive Care doi: 10.1177/0310057X1804600112 – volume: 10 start-page: 2279 issue: 10 year: 2010 ident: 4359_CR9 publication-title: Am J Transplant doi: 10.1111/j.1600-6143.2010.03179.x – volume: 34 start-page: 3142 issue: 8 year: 2002 ident: 4359_CR14 publication-title: Transplant Proc doi: 10.1016/S0041-1345(02)03593-5 – volume: 6 start-page: 274 issue: 5 year: 2010 ident: 4359_CR18 publication-title: Nat Rev Nephrol doi: 10.1038/nrneph.2010.33 – volume: 42 start-page: 377 issue: 2 year: 2009 ident: 4359_CR44 publication-title: J Biomed Inform doi: 10.1016/j.jbi.2008.08.010 – volume: 86 start-page: 1096 issue: 6 year: 2014 ident: 4359_CR16 publication-title: Kidney Int doi: 10.1038/ki.2014.105 – volume: 132 start-page: 614 issue: 4 year: 2020 ident: 4359_CR36 publication-title: Anesthesiology doi: 10.1097/ALN.0000000000003130 – volume: 95 start-page: 1008 issue: 8 year: 2013 ident: 4359_CR8 publication-title: Transplantation doi: 10.1097/TP.0b013e3182855544 – volume: 302 start-page: 1067 issue: 10 year: 2009 ident: 4359_CR12 publication-title: JAMA doi: 10.1001/jama.2009.1310 – ident: #cr-split#-4359_CR46.2 – volume: 101 start-page: 1913 issue: 8 year: 2017 ident: 4359_CR3 publication-title: Transplantation doi: 10.1097/TP.0000000000001409 – volume: 8 start-page: CD010741 issue: 8 year: 2016 ident: 4359_CR24 publication-title: Cochrane Database Syst Rev – volume: 350 start-page: h2147 year: 2015 ident: 4359_CR26 publication-title: BMJ doi: 10.1136/bmj.h2147 – volume: 43 start-page: 795 issue: 6 year: 2017 ident: 4359_CR37 publication-title: Intensive Care Med doi: 10.1007/s00134-017-4772-6 – volume: 11 start-page: 2093 issue: 10 year: 2011 ident: 4359_CR1 publication-title: Am J Transplant doi: 10.1111/j.1600-6143.2011.03686.x – volume: 99 start-page: 997 issue: 5 year: 2015 ident: 4359_CR41 publication-title: Transplantation doi: 10.1097/TP.0000000000000450 – volume: 10 start-page: 838 issue: 6 year: 2017 ident: 4359_CR39 publication-title: Clin Kidney J doi: 10.1093/ckj/sfx040 – volume: 378 start-page: 829 issue: 9 year: 2018 ident: 4359_CR21 publication-title: N Engl J Med doi: 10.1056/NEJMoa1711584 – volume: 77 start-page: 1545 issue: 10 year: 2004 ident: 4359_CR5 publication-title: Transplantation doi: 10.1097/01.TP.0000121763.44137.FA – volume: 86 start-page: 251 issue: 2 year: 2014 ident: 4359_CR10 publication-title: Kidney Int doi: 10.1038/ki.2014.18 – volume: 9 start-page: e1001307 issue: 9 year: 2012 ident: 4359_CR2 publication-title: PLoS Med doi: 10.1371/journal.pmed.1001307 – volume: 378 start-page: 2263 issue: 24 year: 2018 ident: 4359_CR47 publication-title: N Engl J Med doi: 10.1056/NEJMoa1801601 – volume: 373 start-page: 405 issue: 5 year: 2015 ident: 4359_CR11 publication-title: N Engl J Med doi: 10.1056/NEJMoa1501969 – volume: 150 start-page: 604 issue: 9 year: 2009 ident: 4359_CR27 publication-title: Ann Intern Med doi: 10.7326/0003-4819-150-9-200905050-00006 – volume: 314 start-page: 1701 issue: 16 year: 2015 ident: 4359_CR35 publication-title: JAMA doi: 10.1001/jama.2015.12334 – volume: 3 start-page: Cd011671 year: 2019 ident: 4359_CR13 publication-title: Cochrane Database Syst Rev – volume: 96 start-page: 885 issue: 10 year: 2013 ident: 4359_CR4 publication-title: Transplantation doi: 10.1097/TP.0b013e3182a19348 – volume: 371 start-page: 1111 issue: 12 year: 2014 ident: 4359_CR45 publication-title: N Engl J Med doi: 10.1056/NEJMoa1405707 – volume: 5 start-page: 235 issue: 4 year: 2016 ident: 4359_CR25 publication-title: World J Crit Care Med doi: 10.5492/wjccm.v5.i4.235 – volume: 42 start-page: 1585 issue: 7 year: 2014 ident: 4359_CR31 publication-title: Crit Care Med doi: 10.1097/CCM.0000000000000305 |
| SSID | ssj0043934 ssj0017864 |
| Score | 2.3330255 |
| Snippet | Delayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor kidney... Background Delayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor... Delayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor kidney... BackgroundDelayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor kidney... Abstract Background Delayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 428 |
| SubjectTerms | Acidosis Administration, Intravenous Analysis Australia Balanced crystalloid Chloride Chlorides Chronic kidney failure Clinical trials Clinical Trials, Phase III as Topic Costs Delayed graft function Delayed Graft Function - epidemiology Delayed Graft Function - etiology Double-Blind Method Double-blind studies End-stage kidney disease Fluid Therapy - methods Fluids Gluconates - pharmacology Graft Survival Grants Health aspects Health care costs Hemodialysis Hospitals Humans Hyperkalemia Intravenous fluids Intravenous therapy Kidney diseases Kidney transplantation Kidney Transplantation - adverse effects Kidney transplants Magnesium Chloride - pharmacology Medical research Medicine Metabolism Mortality Multicenter Studies as Topic Nephrology New Zealand Organ transplant recipients Peri-operative care Perioperative Care - methods Plasma Postoperative Complications - epidemiology Potassium Chloride - pharmacology Pragmatic Clinical Trials as Topic Public health Quality of Life Registries Saline Solution - pharmacology Sodium Acetate - pharmacology Sodium Chloride - pharmacology Study Protocol Tissue Donors Treatment Outcome |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEDaoB8QF8SZQ0CCBAFHTbGLnwa0LXVWIokptpd6s-FVWbJNqH0jLr2fGSVYbIcGF2ya2k7H388w4Hn_D2Cuf-swnzvHSGlyglLHgWnrJLaFDCGN9-DRw_C07OhdfLuTFVqoviglr6YHbgduvhCiNlEmZm1xY43XqieDE5bKyhZbhHDnavH4x1epgtLKp6I_IFNn-AjV12K-kUMZUljwZmKHA1v-nTt4ySsOAyS0LNLnL7nSuIxy0It9jN119n9067jbHH9z4TDGBaziZN8sG_15AdxTG4bQO9LlDw73TkPoGTRa0zOYzHFyYzFZTu4C348PTM95evPsIFVzPq8vA6roHlMOBUsNxsnx2D0IsIidh3XwPbLPSM8c1uq1Yhg-2zdX0l7PQBcPP8GdIEQI9wTgKgN4ntBEl0HiYUrd_BtJY8CQCtKfD1kBfi-EEHf2rin9dLx3g8goooARrxh_K17CoyF2GpgZivVzjuy7nlV8CmW2CHj4bSwztRVkUtcZh-DG1tVujTP0YBIw-ZOeTw7NPR7xLEsGNzNIl91WSaXxpXHgEBrp33trcFNaNCJxx7IizTyaZT50RsRtVsUYUZkbnVmqPOu0R26mb2j1hIOPEYt3MFVkhHALHGC3QXouUWM-kjtiox4wyHYM6JfKYqbCSKjLV4kwhzlTAmUoi9n7T5rrlD_lr7TFBcVOTuL_DDZwRqpsR6l8zImJvCMiKNBSKZ6ruoAV2kri-1EGGLisuJGUZsd1BTdQsZljcTwXVabaFwsI4TUt0fCP2clNMLSlar3YIERWOU0vipozY43bmbLqEDjz5qNg6H8ypQZ-HJfX0e-A9zxNByQKe_o9BesZuJ0EdSJ7IXbaznK_cc3Qvl_pF0CS_AaSpfGo priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1tb9MwEDYwJISEEIy3wkCHBALEzNLEdhK-oA1WTYihSdukfrMSv4yKLilth1R-PXdOUhYh7VsbO8nZeXx3ts_PMfbKJ1752DmeW4MTlDwSvJReckvoEMJYH5YGDr-rg1PxdSzH7YLbog2r7HRiUNS2NrRGvoNmNkqSHA3up9kvTlmjaHe1TaFxg90k6jIK6UrH6wnXMM2U6A7KZGpngfo67FpSQGMicx73jFHg7P9fM18yTf2wyUt2aHSP3W0dSNhtvvh9dt1Vm-zWYbtFvsnuNAtx0JwvenDtC0UKruBoXi9r_OiATirshTM80GUUDdeOQ0IcNGTQ8J1PscthNL2Y2AW83ds_PuHNn3cfoYDZvDgLXK_bQJkdKGEcJ3totyFEKHIS3s23wdYojeMoUYVl-GBbn0_-OAttiPwUf4bEIdDRjqMA6JNCE2cCtYcJdcPvQCULnkSA5szYCmgNGY7Q_T8v-LfV0gFOuoDCTLBm9CF_DYuCnGioKyAuzBW-62xe-CWQMSdA4rOxxNAOlUVRK-yGnxNbuRXK1PVBQO5DdjraP_l8wNvUEdxIlSy5L2JV4kujzHt0YZTw1qYms25IkI0iR0x-MlY-cUZEblhEJWJTmTK1svSo6R6xjaqu3BMGMoot1lUuU5lwCCRjSoFWXCTEhSbLARt2GNKm5VWn9B5THeZXmdIN7jTiTgfc6XjA3q_vmTWsIlfW3iNormsSI3i4UM_PdKtgdCFEbqSM89SkwhpfJp6IgFwqC5uVMh2wNwRsTXoLxTNFe_wCG0kMYHpX4QjD6aXMB2yrVxP1jekXd0NDt_puof-NzgF7uS6mOymGr3IIER0OWUtirBywx81IWjcJ3XryXPHutDfGem3ul1STH4ENPY0FpRB4erVYz9jtOAx8yWO5xTaW8wv3HN3JZfki6Iy_SSl4oQ priority: 102 providerName: ProQuest |
| Title | Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9% saline on delayed graft function in deceased donor kidney transplantation |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32450917 https://www.proquest.com/docview/2730339617 https://www.proquest.com/docview/2406952279 https://pubmed.ncbi.nlm.nih.gov/PMC7249430 https://doaj.org/article/a449c55297c74dcfb3f8156e75ad8b57 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFDZjkxAviDuFUR0kECDqkSZ2LkgItbAxTWya2Cb1LUp8GRVdMtIOUX495zhJtYgJiZdeYjuxre9cHB9_h7HnNrCh9Y3hiVa4QEk8wXNpJdeEDiGUtu7VwP5BuHsi9iZyssbadEfNBM6vXNpRPqmTarb168fyAwr8eyfwcfh2jnrY7UZSoGIgE44qeQMtU0SCui9Wuwpoe-td5khIHqKtaw_RXHmPjqFyfP5_a-1LZqsbUnnJRu3cZrca5xJGNRrusDVT3GU39pvt83vXPlHU4BIOq3JRIgAAHVYYu_M80GYXddeOXHIcNGpQc5_PcPphZ3Yx1XN4Nd4-Oub1n9fvIIPzKjt1vK8DoCwPlDyOk23UA3DRipw6a6oB6PIinxmeo2OLZXhjXZ5NfxsNTbj8DH-6JCLQUpBjB9A_hTrmBEoLUxr2T0crC5a6APX5sSXQ-2Q4xKXAWca_LBcGcAEGFHKCNb2t5AXMM3KooSyAeDGX-KzTKrMLIMNO4MR7Y4mi3SqNXS1wGr5PdWGW2Kd2DhyK77OTne3jj7u8SSPBlQyDBbeZH-b4UC-2Ft2ZUFitIxVrMyT4ep4hVj_phzYwSnhmmHk54jRUeaRlblHrPWDrRVmYRwyk52usG5o4jIVB4CiVC7ToIiBeNJn32LDFTKoajnVK9TFL3VorDtMaZyniLHU4S_0ee7Nqc14zjPyz9piguKpJ7ODuQlmdpo2ySTMhEiWln0QqElrZPLBECmQimek4l1GPvSQgpyRV2D2VNUcxcJDEBpaOQnRqcakpkx7b7NRE3aO6xa0opK3opljoBUGCrnGPPVsVU0uK5ysMQiR1B64lsVf22MNaclZDQhefvFhsHXVkqjPmbkkx_eaY0SNfUDqBx_81pU_YTd_JveS-3GTri-rCPEVPc5H32fVoEvXZxmi0d7SH3-Ptg8OvfffeBj8_T4Z9p2D-AIS5gl0 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3rT9RAEF8REjUxRvF1ijomEjWyUtrdPkyM4QQC8ggRSPi2tvvAi0eLd4fm_KP8G53ZticXE7757e5225tt57k78xvGXrjIxS60lmdGY4CSBYIX0kluiDuE0Mb5rYHdvXjzSHw6lscz7HdbC0Npla1O9IraVJr2yJfRzAZRlKHB_XD2nVPXKDpdbVto1Gyxbcc_MWQbvt9aw_e7GIYb64cfN3nTVYBrGUcj7vIwLjAICFLn0LrFwhmT6NTYFVpNEFgCeZNh7CKrRWBX8qBAsmNdJEYWDoUA73uVzYkIQ5lZNtdd39v_PDm3SNJYtKU5abw8RAvhz0kphTKSGQ-nzJ_vEvCvLbhgDKcTNS9Yvo3b7FbjssJqzWN32Iwt59m13eZQfp7drLf-oK5ountljXITx7A_qEYVshmgWwxdXzUEbQ9T_9uBb8GDphNqhPU-vmTY6J_3zBBeddcPDnn95fU7yOFskJ94dNkloF4S1KKOkwU2S-BzIjkRbwdLYCqkxnKkqMQxvLGpTnu_rIEmKb-PH32rEmiBzpEA9IKhzmyBykGPHsMPD14LjkiAukptDLRrDfsYcJzmfGc8soBvGCixBWcGb7NFGObktkNVAqFvjvG_Tga5GwG5DyQCeG8c0XQmZpDUEh_Dt54p7Rhpap-Bl5V77Oi_sNV9NltWpX3IQAahwbmxTeNUWGQkrQuBfoOICH1NFh220vKQ0g2SOzUU6Ssf0aWxqvlOId8pz3cq7LA3k2vOahyTS2d3iTUnMwmD3P9QDU5Uo9JULkSmpQyzRCfCaFdEjqCHbCJzkxYy6bCXxNiKNCWSp_Om4AMXSZhjajVGmcaAVmYdtjA1EzWcnh5uRUM1Gnao_uqDDns-GaYrKWuwtMgiypd1S8LI7LAHtSRNloSBBPnKeHUyJWNTa54eKXtfPf56EgpqWvDocrKeseubh7s7amdrb_sxuxF6JSB5KBfY7Ghwbp-gMzsqnjYaBNiX_620_gBZc7eu |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3rb9MwEDdjSAgJIRivwoBDYgLEzNLEzgMJoY2t2thDk7ZJ-2YSP0ZFl4y2A5U_jb-OOycpq5D2bd_a2knPyT3tu98x9spFLnahtTwzGgOULBC8kE5yQ9whhDbObw3s7sWbR-LLsTyeY3_aWhhKq2x1olfUptK0R76CZjaIogwN7opr0iL213ufzn5w6iBFJ61tO42aRbbt5BeGb6OPW-v4rpfCsLdx-HmTNx0GuJZxNOYuD-MCA4IgdQ4tXSycMYlOje3SyoLAEuCbDGMXWS0C282DApcQ6yIxsnAoEHjf6-xGEskuyVhyPA32ukkai7ZIJ41XRmgr_IkpJVNGMuPhjCH0_QL-twoXzOJsyuYFG9i7y-40zius1tx2j83ZcoHd3G2O5xfY7XoTEOrapvvX1ilLcQL7w2pcIcMBOsiw5uuHoO1m6n878M140IhCjbU-wNcNvcF534zgzdrGwSGvv7z9ADmcDfMTjzO7DNRVgprVcbLFZhl8diQn4u1wGUyF1FiOFJU4hjc21Wn_tzXQpOcP8KNvWgIt5DkSgP4w1DkuUDno02P46WFswREJUNerTYD2r2EfQ4_TnO9Mxhbw_QKluODM4H22BKOcHHioSiAczgn-18kwd2MgR4KEAe-NI5pOxwySWuJj-N43pZ0gTe0z8FLzgB1dCVM9ZPNlVdrHDGQQGpwb2zROhUVG0roQ6EGIiHDYZNFh3ZaHlG4w3am1yED52C6NVc13CvlOeb5TYYe9m15zViOaXDp7jVhzOpPQyP0P1fBENcpN5UJkWsowS3QijHZF5AiEyCYyN2khkw57TYytSGcieTpvSj9wkYQ-plZjlG4MbWXWYYszM1HX6dnhVjRUo2tH6p9m6LCX02G6kvIHS4ssonyBtyS0zA57VEvSdEkYUpDXjFcnMzI2s-bZkbL_zSOxJ6Gg9gVPLifrBbuJqkrtbO1tP2W3Qq8DJA_lIpsfD8_tM_Rqx8Vzrz6Afb1qffUXfSG6fg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Study+Protocol+for+Better+Evidence+for+Selecting+Transplant+Fluids+%28BEST-Fluids%29%3A+a+pragmatic%2C+registry-based%2C+multi-center%2C+double-blind%2C+randomized+controlled+trial+evaluating+the+effect+of+intravenous+fluid+therapy+with+Plasma-Lyte+148+versus+0.9%25+saline+on+delayed+graft+function+in+deceased+donor+kidney+transplantation&rft.jtitle=Trials&rft.au=Collins%2C+Michael+G.&rft.au=Fahim%2C+Magid+A.&rft.au=Pascoe%2C+Elaine+M.&rft.au=Dansie%2C+Kathryn+B.&rft.date=2020-05-25&rft.issn=1745-6215&rft.eissn=1745-6215&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs13063-020-04359-2&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13063_020_04359_2 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |